AA: 438-506 • Tag: N-terminal biotin labeling • MW: 8.053 kDa
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SARS-CoV-2 Spike Glycoprotein Receptor Binding Motif

Item No. 30428

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein Receptor Binding Motif
Purity
≥95%
Amino Acids
438-506
MW
8.053 kDa
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
Water: soluble
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $1,467

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surface glycoprotein receptor binding motif is a fragment of the surface glycoprotein, also known as the spike glycoprotein, encoded by the S gene in SARS-CoV-2 RNA.1 It contains amino acids 438-506 of the full-length SARS-CoV-2 spike glycoprotein sequence. SARS-CoV-2 is a member of the Betacoronavirus genus of viruses and has 88% sequence identity with two bat-derived SARS-like CoVs.2 The SARS-CoV-2 genome contains approximately 30 kilobases that encode four structural proteins: spike, envelope, membrane, and nucleocapsid.1,3 The SARS-CoV-2 spike glycoprotein is located on the outer envelope of the virion and is comprised of an S1 and S2 subunit divided by a furin S-cleavage site not found in other SARS-CoVs.4,5 The S1 subunit contains the N-terminus and a receptor binding domain (RBD; Item No. 30429), and the S2 subunit contains a fusion peptide, two heptad repeats, and the C-terminal domain.4 The SARS-CoV-2 receptor binding motif is a component of the RBD that shares 73% sequence identity to that of SARS-CoV, and can bind to human angiotensin-converting enzyme 2 (ACE2), which is the host cell surface receptor for both SARS-CoV and SARS-CoV-2.4,6,7,5 SARS-CoV-2 is the causative agent of COVID-19, a primarily respiratory illness characterized by fever, cough, and shortness of breath that can lead to life-threatening complications.8,9,10 Cayman's SARS-CoV-2 Spike Glycoprotein Receptor Binding Motif contains an N-terminal biotin tag and a disulfide bridge between Cys480 and Cys488.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kandeel, M., Ibrahim, A., Fayez, M., et al. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. J. Med. Virol. 92(6), 660-666 (2020).

    2. Lu, R., Zhao, X., Li, J., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395(10224), 565-574 (2020).

    3. Ahmed, S.F., Quadeer, A.A., and McKay, M.R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12(3), E254 (2020).

    4. Liu, Z., Xiao, X., Wei, X., et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J. Med. Virol. 92(6), 595-601 (2020).

    5. Walls, A.C., Park, Y.-J., Tortorici, M.A., et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181(2), 281-292 (2020).

    6. Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2), 271-280 (2020).

    7. Tian, X., Li, C., Huang, A., et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 9(1), 382-385 (2020).

    8. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., et al. Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur. Rev. Med. Pharmacol. Sci. 24(4), 2012-2019 (2020).

    9. Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 191, 145-147 (2020).

    10. Yang, F., Shi, S., Zhu, J., et al. Analysis of 92 deceased patients with COVID-19. J. Med. Virol. 92(11), 2511-2515 (2020).